In Brief
Gelbard-Sagiv, Magidov et al. pharmacologically down-and upregulated NE signaling while subjects performed visual detection and discrimination tasks. They demonstrate that NE modulates perceptual sensitivity and accuracy, as well as late visually evoked EEG and fMRI responses, suggesting a key enabling role for NE in perceptual awareness.
INTRODUCTION
An identical sensory stimulus might lead to a different chain of neuronal responses and perceptual experience, depending on the behavioral state of the organism or on cognitive factors, such as vigilance, attention, and intention. Neuromodulation may play a key role in determining the neural and perceptual fate of sensory events. Indeed, neuromodulatory activity affects cortical processing via multiple mechanisms that include excitation and inhibition balance, local synchrony, and the interplay between bottom-up and top-down signaling. Such processes may constitute necessary enabling factors for full-fledged processing of external sensory events, giving rise to perceptual awareness [1, 2] .
Several lines of evidence suggest that noradrenaline (NE) may specifically play a key role in sensory processing [3] [4] [5] [6] , although neuromodulatory systems partially overlap and present some redundancy. Elevated NE levels have been shown to enhance responses in the auditory [7] [8] [9] , visual [10, 11] , olfactory [12] , and somatosensory modalities [13] [14] [15] by improving the signalto-noise ratio (SNR) of sensory signals [7, 16, 17] , lowering response thresholds [16] [17] [18] , shortening response latencies [12, 14] , decreasing jitter in spike timing [8, 14] , sharpening tuning curves [19] , and facilitating intra-cortical communication [20] . These effects of NE on sensory responses suggest a facilitation of perceptual processing also at the functional level. Indeed, NE activity was linked to orienting toward behaviorally relevant stimuli [21] [22] [23] [24] and is strongly related to the P300 [25] eventrelated potential (ERP) component that correlates with perceptual awareness [26] . Interestingly, during rapid eye movement (REM) sleep, while consciousness exists (dreaming) but is largely unaffected by external sensory stimuli [27] , NE signaling is silent. Despite such correlations, direct demonstrations linking NE signaling and perception of external sensory stimuli are limited. Such investigation is best performed in humans who can readily report their subjective perception, yet causal investigations of NE effects on sensory perception and sensory-evoked activities in humans are scarce. Although effects of NE have been reported on auditory discrimination abilities [28] , on response times in visual discrimination [29, 30] , and on gustatory perceptual thresholds [31] , the generalization of these findings and the extent to which perceptual effects can be separated from attentional ones remains unknown.
Here, we tested the hypothesis that NE has a causal role in enabling perception of external sensory stimuli by pharmacologically and bi-directionally manipulating NE signaling in a doubleblind, placebo-controlled crossover design. We examined the effects of altered NE levels on visual detection and discrimination and on neural responses as measured with electroencephalography (EEG) and blood-oxygen-level-dependent (BOLD) fMRI. We used simple stimuli at threshold contrast (individually titrated for each subject) and simple yet well-controlled tasks, enabling the separation of sensitivity and discriminability versus response bias and attention. To best delineate the spatial and temporal stages at which neuromodulation may exert its differential effects, we focused on the visual modality given its well-defined hierarchy and the extensive knowledge on activity patterns that correlate with visual perception [26, 32] .
If NE indeed regulates sensory perception, then reducing NE signaling should impair perception and boosting NE signaling may improve it. We predicted that the use of liminal stimuli would reveal such bi-directional effects even for moderate NE modulations. Because robust early responses in primary sensory regions are observed also when NE signaling is reduced (e.g., during sleep) [33, 34] , we postulated that noradrenergic manipulations will primarily modulate late sensory responses.
RESULTS
In the main experiment (Exp1; behavioral and EEG), we evaluated the effect of clonidine [35, 36] (0.15 mg; an a2 agonist reducing NE signaling) and reboxetine [37, 38] (4 mg; selective noradrenaline reuptake inhibitor increasing NE signaling) relative to placebo in 19 participants using a double-blind crossover design. After defining a liminal Gabor contrast in each session using a staircase procedure (STAR Methods), subjects performed visual detection and discrimination tasks before drug administration (before drug) and repeated the same experiments 2 hr after drug adminisration, concomitant with EEG recording (after drug). Peripheral (blood pressure and pupillometry) and subjective (sleepiness score) measures of arousal were monitored throughout each experimental session.
Noradrenergic Drugs Exert Robust Effects on Peripheral and Subjective Measures of Arousal
We first evaluated the effects of noradrenergic drugs on peripheral and subjective measures of arousal to verify the effectiveness of the drugs during the after-drug session. Blood pressure and subjective vigilance were measured at the beginning and at the end of the before-drug and after-drug sessions (STAR Methods), as well as every 30 min during the 2-hr wait period. A two-way repeated-measures ANOVA of mean arterial pressure (MAP %change ) values, with drug (clonidine, placebo, and reboxetine) and time from drug administration (0.5, 1, 1.5, 2, and 3 hr) as factors, revealed a main effect for drug (F(2,18) = 29.21; p = 2.9 3 10 À8 ) and an interaction between time and drug (F(4,18) = 7.72; p = 1.4 3 10
À8
), indicating a robust effect of drug administration on blood pressure that unfolded with time. Post hoc comparisons revealed that, as expected [39] , clonidine decreased MAP values relative to placebo starting from 1 hr post-drug administration ( Figure 1B ; MAP %change = À7.84% ± 7.41% [clonidine] versus 1.12% ± 9.10% [placebo; mean ± SD]), and this significant decrease lasted until the end of the session at 3 hr post-drug administration (MAP %change = À10.39% ± 9.35% [clonidine] versus 2.40% ± 4.44% [placebo]; t(18) > 3.99; p < 0.001 at all time points; paired two-tailed t test). Reboxetine showed a trend for increasing MAP values relative to placebo that did not reach significance (p < 0.15 at 1.5 and 2 hr; paired two-tailed t test). , lowering NE levels (NEÀ); 4 mg reboxetine (NE reuptake inhibitor; green), increasing NE levels (NE+); or placebo (blue) in three double-blind, counterbalanced experimental sessions conducted a week apart at same time of day. Each session was composed of a ''before-drug'' behavioral session (1 hr prior to drug administration; left horizontal black bar) with visual detection and discrimination tasks and an ''after-drug'' behavior session (2 hr following drug administration; right horizontal black line) with identical tasks and scalp EEG monitoring. Visual contrast levels corresponding to threshold detection and discrimination (50% and 75% correct, respectively) were determined at the beginning of each before-drug session. (B) Percent change of mean arterial pressure (MAP) measured before and after the behavioral sessions and every 30 min during the 2-hr wait period (indicated by ticks on the timeline in A). Small circles denote individual subject data at the beginning of the after-drug session. (C) Percent change of subjective vigilance measured intermittingly (STAR Methods) at same time points as MAP. (D) Percent change of pupil diameter (after-drug relative to before-drug) during baseline visual fixation intervals (STAR Methods). Red or green asterisks represent significant differences in a paired two-tailed t test comparing NEÀ or NE+ to placebo, respectively. Error bars denote SEM across participants (n = 19). *p < 0.05; ***p < 0.001. See also Figures S1A-S1D for actual MAP and subjective sleepiness values.
ANOVA for changes in subjective vigilance likewise revealed a main effect for drug (F(2,18) = 21.19; p = 8.3 3 10
À7
) and time (F(2,18) = 12.62; p = 7.8 3 10
À8 ), and an interaction between time and drug (F(4,18) = 6.26; p = 6.1 3 10
), indicating a robust effect of drug administration on subjective vigilance that unfolded with time. Planned comparisons revealed that subjects felt more tired after clonidine administration relative to placebo: clonidine decreased subjective vigilance starting at 1 hr post-drug administration ( Figure 1C ; vigilance-score %change = À16.75% ± 26.15% [clonidine] versus 12.10% ± 16.53% [placebo]), and this decrease lasted until the end of the session (vigilance-score %change = À40.61% ± 33.48% [clonidine] versus À4.95% ± 31.17% [placebo]; t(18) > 3.64; p < 0.002 at all time points; paired two-tailed t test). Accordingly, some subjects reported feeling ''foggy'' on the Stanford Sleepiness Scale (STAR Methods; see Figure S1B for individual ratings). Reboxetine, on the other hand, led to stable subjective vigilance scores throughout the session that were comparable to placebo, except for 1.5 hr post-drug administration, where reboxetine was associated with lower vigilance than placebo (t(18) = 2.57; p = 0.02; paired two-tailed t test). Given the well-established relationship between central Locus Coeruleus (LC)-NE activity and pupil diameter [40], we also examined the effects of the noradrenergic drugs on baseline pupil diameter during fixation intervals at the beginning of each experiment. Potential changes due to drug administration were evaluated by calculating percent change of the average after-drug pupil diameter relative to the average before-drug value (STAR Methods). A one-way repeatedmeasures ANOVA on pupil-diameter %change values revealed a significant difference between the drugs (F(2,18) = 49.18; p = 5.1 3 10 À11 ). Planned comparisons showed that clonidine reduced pupil diameter relative to placebo ( Figure 1D ; pupildiameter %change = À14.51% ± 8.54% for clonidine versus À0.45% ± 7.15% for placebo, t(18) = 5.8; p < 0.0001; paired two-tailed t test), and reboxetine elevated it (pupil-diameter %change = 10.57% ± 10.21%; t(18) = 4.03; p < 0.0001). Pupil diameter was stable under placebo (two-tailed t test against zero: t(18) = 0.27; p = 0.79). These changes in pupil diameter confirm the effectiveness of the drugs at the time of the ''afterdrug'' experiment. Importantly, such changes (±15%) in pupil diameter are of the order of typical ongoing fluctuations and were not correlated at the individual subject level with behavioral or neural effects ( Figure S1E ). Altogether, clonidine exerted robust long-lasting effects on MAP, vigilance scores, and pupil diameter, indicating reduced NE signaling. Reboxetine was associated with robust elevation of pupil diameter. Overall, peripheral and subjective measures of arousal confirmed the effectiveness of noradrenergic drugs at the desired time of after-drug experiments. Note that, although the drugs had significant effects on MAP, vigilance scores and pupil diameter at the group level, there was significant variability in these effects across individuals ( Figures 1B-1D , small circles exhibiting overlap between drug conditions; also see Figures S1A-S1D for actual MAP values and sleepiness ratings). Thus, it was not possible for the experimenters to reliably infer the drug from peripheral and subjective measures. Of note, differential effects of drugs at a fixed dose (that stem from participant weight and other factors) introduce variability that makes it more difficult to reveal consistent effects on behavior and neural measures.
Noradrenaline Affects Liminal Visual Detection and Discrimination
In the detection paradigm, participants reported the presence of a Gabor patch, whose contrast was set at threshold performance (50% hits; low false alarm rate) using a staircase procedure in each ''before-drug'' session separately (Figure 2A ; STAR Methods). Seventeen participants completed this paradigm for all drugs in both the before-and after-drug sessions (six sessions per participant). Sensitivity index (d') and response bias (criterion) were calculated based on the hit-and false-alarm rates (STAR Methods; see Figure S2A for individual before-drug and B A Figure 2 . Visual Detection and Discrimination Tasks
Participants were instructed to fixate on a central point during each trial. The color of the fixation point signaled the different stages of the trial: red for stimulus presentation; green for report; and black during inter-trial intervals. (A) Detection task. Subjects were prompted to begin the trial at will. Trial started with a 300-to 700-ms pre-stimulus red fixation, followed by 100 ms central presentation of a left-or right-tilted threshold contrast Gabor patch and 700-1,000 ms post-stimulation red fixation. In half of the trials, no Gabor patch was presented. Next, a green fixation appeared, prompting participants to report presence or absence of stimulus via button press. In addition, participants reported rare occurrences (5%-8% of trials) of short empty black fixation circles (150 ms duration) by a button press, and hit rate on this task was used as a measure of sustained attention levels. (B) Discrimination task. Structure of the task is similar to the detection task but with different durations. Here, the Gabor patch was presented in all trials, and participants first reported its orientation and then rated subjective visibility on a perceptual awareness scale (PAS) ranging from 0 (saw nothing) to 3 (saw a clear image). Participant also completed an additional discrimination block with supra-threshold stimuli and no subjective visibility ratings.
after-drug values for all behavioral measures in the detection paradigm). To test our directional hypothesis that performance will follow clonidine (NEÀ) < placebo < reboxetine (NE+), we analyzed the differences in sensitivity between the after-drug and the before-drug sessions using a permutation-based drug order analysis, in which we counted the number of observations in the hypothesized order and calculated its ranking in a distribution created by randomly shuffling drug labels (STAR Methods). This analysis revealed that the number of observations in the hypothesized order in the actual data was larger than this number in 99.7% of random permutations (p = 0.003; Figure S2C ), reflecting that the reduction in sensitivity was largest under clonidine, greater than both placebo and reboxetine ( Figure 3A Figure S2A ; clonidine versus placebo: p = 0.04; clonidine versus reboxetine: p = 0.001; Wilcoxon signed-rank one tail test). The overall reduction in performance common to all drug conditions could reflect fatigue in the after-drug session (2 hr after drug administration). Interestingly, higher NE levels under reboxetine seem to counteract this wear-out effect. Importantly, NE drugs did not change response bias: the change in criterion was not significantly different between drugs (Figures 3B and S2A; criterion after-before = 0.05 ± 0.50 [clonidine], À0.11 ± 0.41 [placebo] , and À0.08 ± 0.48 [reboxetine]; p = 0.22; drugorder permutation analysis), nor could we reveal significant differences between drugs in sustained-attention performance in the 11 participants who performed the simultaneous sustained attention task (STAR Methods; Figure S2A ; attention-accuracy after-before = 0. In the discrimination task, participants reported the orientation of a Gabor patch whose luminance contrast was set at threshold discrimination performance (75% correct) using a staircase procedure in each before-drug session separately ( Figure 2B ; STAR Methods) and then rated their subjective visibility on the perceptual awareness scale (PAS). Eighteen participants completed this paradigm for all drugs in both the before-and after-drug sessions (six sessions per participant). As was the case for detection performance, we found that discrimination accuracy followed the hypothesized order ( Figure 3C ; p = 0.002; drug-order permutation analysis; Figure S2D ), reflecting that the reduction was largest under clonidine and smallest under reboxetine (acc after-before = À0.12 ± 0.09 [clonidine]; À0.06 ± 0.12 [placebo]; À0.01 ± 0.09 [reboxetine]). Nonparametric paired comparisons confirmed the results of this analysis ( Figure S2B ; clonidine versus placebo: p = 0.05; reboxetine versus placebo: p = 0.025; reboxetine versus clonidine: p = 0.0002; Wilcoxon signed-rank one tail test). In eleven participants who reported their subjective visibility in both the before-and after-drug sessions (STAR Methods), we found that subjective visibility was similarly affected by the drugs (Figures 3D and S2E ; p = 0.013; drug-order permutation analysis; PAS after-before = 0.21 ± 0. 27 [clonidine], 0.05 ± 0.27 [placebo] , and 0.001 ± 0.37 [reboxetine]). Nonparametric paired comparisons between drugs were in line with this analysis (asterisks on Figure S2B ; clonidine versus placebo: p = 0.04; clonidine versus reboxetine: p = 0.06; clonidine versus reboxetine: p = 0.002; Wilcoxon signed-rank one tail test). In eleven participants who performed the simultaneous sustained attention task, performance did not significantly follow the hypothesized order (p = 0.12; drug-order permutation analysis), nor was it significantly different between drugs in the nonparametric paired comparisons ( Figure S2B) . Importantly, the change in accuracy under clonidine was not correlated with the change in performance on the attention task (r(9) = 0.19; p = 0.58; Pearson correlation); however, these measures were correlated under reboxetine (r(8) = 0.76; p = 0.01; Pearson correlation).
Accuracy on a separate supraliminal (high-contrast) discrimination task (STAR Methods) was at ceiling in all drug conditions (acc after = 0.98 ± 0. Error bars represent SEM across participants (n = 17/18 for detection/ discrimination). Individual data points are overlaid, color-coded for subject identity (each participant is denoted by the same color in all paper figures). Black and gray dashed lines connect observations in or against the hypothesized direction (NEÀ < placebo < NE+), respectively. Note that, for criterion, the hypothesized direction is reversed (stricter criterion under clonidine and relaxed criterion under reboxetine). Asterisks represent statistical significance via drug-order permutation-based analysis (STAR Methods). *p < 0.05; **p < 0.01; NS, not significant. Data for these and other behavioral measures in the before-drug and after-drug sessions separately, and significance in nonparametric paired tests between drugs, appear on Figure S2 .
Performance on the simultaneous sustained attention task did not follow the hypothesized order either (p = 0.45; drug-order permutation analysis).
In summary, NE signaling affected the detection and discrimination of liminal visual stimuli, whereas response bias and performance on a simultaneous attention task were largely unaffected. These results indicate that NE signaling causally influences visual perception in a specific manner that goes above and beyond effects on other cognitive faculties (Discussion).
Altered NE Signaling Directionally Affects Visually Evoked Activity
To determine whether drug-induced behavioral changes were associated with changes in visually evoked electrical activity, and when such changes may occur, we recorded high-density (256-channel) EEG in nineteen participants as they performed both liminal and supraliminal visual discrimination paradigms in the after-drug sessions (STAR Methods). Although the ERPs in the liminal discrimination paradigm were enhanced in perceived as compared to unperceived trials at the group level ( Figures  S3D-S3E ), they did not exhibit well-defined visual components [41, 42] (Figures 4B, S3D , and S3E) and thus did not allow a rigorous statistical comparison between the drugs.
The more sensitive measure of inter-trial phase coherence (ITPC) revealed a robust low-frequency (2 or 3 Hz) response in the 200-to 600-ms period after stimulus onset (this time-frequency region of interest [tfROI] is marked by a rectangle in Figure 4A ). Mean ITPC in this tfROI in a predefined occipital ROI (Oz electrode and immediate neighbors) was directionally modulated by the NE manipulation according to the hypothesized order (p = 0.038; drug-order permutation analysis), indicating that the evoked response was weakest under clonidine and strongest under reboxetine ( Figures 4C and S3A ). Paired comparisons showed that the ITPC measure was significantly higher under reboxetine than under placebo (p = 0.04; Wilcoxon signed-rank one-tail test) and clonidine (p = 0.006). Importantly, mean ITPC in the above-mentioned tfROI was highly correlated to the change in behavioral accuracy across individuals ( Figure 4D ; r(52) = 0.53; p = 0.00005; Pearson correlation), suggesting a strong connection between the perceptual effects and the underlying evoked activity. This relationship between ITPC and behavior was also evident when looking separately at perceived versus unperceived trials ( Figure S3C ).
Although the ITPC was in general agreement with the ERP results (Figures 4A, 4B, and S3), the temporal resolution of the ITPC analysis did not allow the localization of the effects to specific time windows. To overcome this challenge, we used the data from the supraliminal (high-contrast) discrimination paradigm that yielded typical ERP responses with clear visually evoked components. supporting the specificity of NE effects to the $200-ms time window. Comparing the spatial topography of ERPs under the different drugs ( Figure S4B ) showed that the difference between clonidine and placebo around 200 ms was predominant in occipital electrodes and confirmed our a priori selection of the occipital ROI for analysis of visually evoked potentials. Altogether, visual responses to liminal stimuli displayed increased consistency with increasing NE signaling, mirroring the changes in behavioral performance brought about by the noradrenergic drugs. Furthermore, the responses to supraliminal stimuli were identical at early stages (<150 ms) but delayed around 200 ms under reduced NE signaling, thereby pointing to the time interval at which NE modulation exerts its effects (Discussion).
NE Signaling Modifies Visually Evoked BOLD fMRI Responses in High-Level Visual Areas
To better characterize the brain regions affected by the NE pharmacological manipulation, we conducted an additional set of fMRI experiments in six subjects (STAR Methods), measuring BOLD fMRI responses to images presented at full, medium, and low-contrast levels (100%, 10%, and 4%, respectively). We administered the same noradrenergic drugs, again employing a double-blind placebo-controlled crossover design as in the first behavioral/EEG experiment. We presented line drawing object images ( Figure 5B ) to allow the differentiation between low-level and high-level visual areas. A whole-brain group-level map (fixed effects) contrasting visual responses under placebo versus clonidine in response to objects at all luminance contrasts levels ( Figure 5A ) showed a selective decrease in visually evoked activity in high-level visual regions under clonidine (orange patches), whereas other cortical regions did not show significant changes. A comparison between reboxetine and clonidine yielded a similar pattern of results, whereas comparing placebo versus reboxetine did not yield significant differences (not shown).
ROI deconvolution analysis (STAR Methods) focusing on the left lateral occipital complex (LO) that showed the most prominent difference in the group map (ROI determined for each subject separately using a separate visual localizer experiment; STAR Methods) revealed that activity in response to full-contrast stimuli was largely preserved across drugs whereas responses evoked by low-contrast stimuli significantly followed the hypothesized order of response strength (NEÀ < placebo < NE+; p = 0.007 for 4% contrast and p = 0.02 for 10% contrast; drug-order permutation analysis; Figures 5B and S5) . Altogether, the same noradrenergic manipulation associated with changes in behavioral performance and late electrical evoked responses was found to primarily affect BOLD fMRI activity in high-level visual areas, and these effects reached statistical significance already with a limited number of participants, attesting to their robustness.
DISCUSSION Noradrenergic Signaling Causally Affects Visual Perception and Late Visually Evoked Activity
In this study, we bi-directionally manipulated NE levels in healthy participants and examined the influence on visual detection and discrimination as well as on underlying neural activity. We found that detection and discrimination performance and evoked activity measured by EEG and fMRI were robustly and bi-directionally modulated by the NE manipulations. More specifically, we show that detection sensitivity (d'), discrimination accuracy, and subjective visibility all followed the hypothesized order (NEÀ < placebo < NE+; Figures 3 and S2) whereas decision bias (response criterion) and sustained attention performance (A) Multi-subject analysis (fixed effects; n = 6) map presented in an unfolded cortical format, contrasting responses to object images at all contrast levels under placebo versus clonidine (orange placebo > clonidine). Clonidine impaired the BOLD response in high-level visual areas and spared the activity in other cortical regions. This impairment was most prevalent in the lateral occipital complex (denoted by a white contour; defined for each subject in a separate visual localizer by objects versus textures). (B) LO average hemodynamic response function (extracted by a deconvolution procedure) for the different drugs and contrast levels. Note that, although the full-contrast activation was largely unaffected by the drugs (left panel), the response to the lower contrasts images modulated with NE levels (middle and right panels). Asterisks represent statistical significance via drug-order permutation-based analysis (STAR Methods); *p = 0.019; **p = 0.007. Error bars represent SEM across participants. See Figure S5 for individual subject time courses.
did not follow this order. Accordingly, the consistency of the EEG-evoked response also followed this hypothesized order ( Figure 4C ) and was highly correlated to the observed changes in behavioral performance, in line with the notion of signal reproducibility as a marker of conscious awareness [44, 45] . Examining visual ERPs evoked by supraliminal stimuli, we were able to reveal that the effects of reduced NE signaling primarily affect neuronal responses around 200 ms (an interval commonly regarded as a temporal correlate of visual awareness) [46] where the electrical response was delayed relative to placebo. In contrast, earlier activity (associated with pre-perceptual processes) [46] was unaffected ( Figure S4 ). fMRI results confirmed the specific influence of NE on late visual processing, where activity in high-level visual cortex, commonly regarded as a spatial correlate of visual awareness [47] ( Figure 5 ) again followed our hypothesized order. Thus, the results support our hypothesis that NE signaling plays a key causal role in enabling early visual responses to effectively drive activity in late stages of visual processing critical for perceptual awareness.
Can Enhancement of Noradrenergic Tone Improve Perception and Neural Responses?
Reboxetine effects were more variable than those of clonidine. This might reflect the inverted U shape of noradrenergic signaling [48] , according to which performance may be impaired by overly high noradrenaline levels (relative to optimum). Another possibility is that visual perception and underlying neural activity are ''at ceiling'' for salient stimuli and cannot be further improved, as suggested by the observation that NE enhancement did not lead to a stronger EEG response ( Figure S4 ) or BOLD fMRI response ( Figure 5B , left panel) to supra-threshold stimuli. However, when the stimulus is weak, enhanced NE signaling can improve perception ( Figure 3 ) and underlying neural activity (Figures 4 and 5) . The fact that statistical comparisons between reboxetine and clonidine were always more significant than comparisons between placebo and clonidine supports the notion that perceptual and neuronal effects under reboxetine were greater than those of placebo.
Effects of Noradrenergic Activity on Sensory Processing
The LC-NE system and its widespread projections to the forebrain have been traditionally implicated in mediating arousal [3, 49] . With time, a large body of studies further established the beneficial effects of LC-NE signaling on the magnitude and precision of sensory responses [3] [4] [5] [6] , leading to refined views of its functions that include optimization of behavioral performance [48, 50] and reconfiguration of functional networks [51] . However, despite the seemingly straightforward connection between enhanced sensory responses at the neuronal level and perception, a causal link between LC-NE activity and perception has not been demonstrated. Endogenous changes in LC activity, inferred by pupillometry [40] , have been shown to correlate with behavioral performance on visual tasks [52-55], but such effects were typically attributed to changes in attention, decision making, or confidence rather than to sensory perception per se. Systematic causal investigations of NE levels on sensory processing in humans are scarce [28] [29] [30] , and their design did not allow separating perceptual effects from those of sedation and selective attention. The use of threshold stimuli revealed beneficial effects of elevated NE on some gustatory perceptual thresholds [31] , but the generalization of these findings remained unknown. Here, we used simple stimuli at threshold (individually titrated for each subject), allowing the demonstration of bi-directional effects, and used simple yet well-controlled detection and discrimination tasks, enabling the separation of sensitivity and discriminability versus response bias and attention. Taken together, the present results establish the causal effect of NE signaling on sensory perception, above and beyond its effects on higher cognitive processes [3, 5, 56] . Moreover, by combining EEG and fMRI in the visual modality where spatiotemporalevoked activity is well characterized, we were able to associate the perceptual effects with a specific temporal interval and spatial location along the visual processing hierarchy.
What could be the mechanisms by which LC-NE activity promotes late sensory responses? Several non-mutually exclusive processes could be at play. Noradrenergic tone boosts the gain and SNR in early sensory areas [7] , so it could be that higher-fidelity activity in early regions constitutes a more effective input to high-level nodes. Another possibility is that NE activity enhances intra-cortical communication [20, 51] , either via direct intercortical pathways or possibly through high-level thalamic nuclei mediating cortico-thalamic-cortical signaling [57] . In addition, NE signaling may affect HCN channels that have been suggested to mediate the link between bottom-up and top-down signaling [58] . Future studies with millisecond temporal resolution and cell-type specificity, such as optogenetics, are needed to resolve the downstream mechanisms mediating the effects observed here.
Limitations and Possible Confounding Factors
Any systemic reduction of LC-NE signaling inevitably entails sedation (indeed clonidine is clinically used as a sedative) [59] . Here as well, NE reduction led to decreased vigilance ( Figure 1C ), as reflected in higher subjective sleepiness scores ( Figures S1B  and S1D ). To what extent can the behavioral and neural impairment under clonidine be explained by changes in vigilance? Several observations suggest that sedation is not sufficient to explain the results. First, there was no correlation at the individual subject level between subjective sleepiness and the behavioral or neural effects ( Figure S1E, middle column) . Second, each trial in the EEG/behavioral experiments was self-paced, i.e., subjects were instructed to initiate a trial only when they are ready, minimizing the effects of fatigue on trial-by-trial performance. Third, in the fMRI experiment, the different levels of image contrast were intermixed in a rapid event-related pseudorandom design, yet the neural impairment was only evident at low contrast levels. Fourth, eye tracking during the EEG/behavioral experiment allowed us to discard any trials associated with partial eye closure (STAR Methods). Fifth, response bias and performance on the demanding sustained attention task remained stable under clonidine (Figures 3, S1A , and S1B). Sixth, the effects on neuronal responses were highly localized in the temporal (EEG) and spatial (BOLD fMRI) domains, leaving early visual processing intact, further arguing against global sedation. Finally, most of the observed effects are bi-directional although vigilance was not bi-directionally affected ( Figure 1C) . Whereas all these arguments suggest that sedation alone cannot explain the behavioral and neural effects of clonidine, they cannot completely rule out this concern. Future studies (for example, animal models employing detailed sensory psychophysics with increased flexibility in drug choice and dosage) will be needed to further separate perceptual and neuronal effects from those of sedation.
Could the results simply reflect attentional or metacognitive effects? Previous studies suggested that behavioral impairment associated with reduced NE signaling reflects attentional processes [60, 61] . In our experiments, performance on the sustained attention task was not significantly affected by clonidine. In addition, as opposed to these studies, here, participants were required to press a button when they are ready to initiate a trial. It has been shown that stimuli that temporarily increase arousal like white noise [62, 63] or a target in a rapid serial visual presentation (RSVP) task [64] can compensate for the tonic decrease in alertness caused by clonidine and completely reverse its effects, probably via a phasic NE response. Yet despite the fact that the button press initiating each trial constituted an arousing stimulus, performance was still impaired under clonidine, suggesting that the effects do not likely stem from a general decrease in alertness. Interestingly, a recent study demonstrated a metacognitive enhancement by NE blockade [65] . Although the mechanisms of noradrenergic beta-blockers and a2 agonists are different, possible metacognitive enhancement under clonidine strengthens the notion that the impaired perceptual performance observed here is unlikely to simply reflect changes in attentional processes. Reboxetine, on the other hand, showed a trend for better performance on the sustained-attention task during visual discrimination, which was correlated with the improvement in accuracy. Although we cannot rule out the possibility that reboxetine exerted its effects via attentional mechanisms, we point out that these mechanisms may reflect bottom-up endogenous attention rather than top-down signaling from fronto-parietal networks. If so, such effects are compatible with direct influence on sensory pathways.
Can the results stem from changes in blood pressure (Figure 1B) ? We could not reveal any correlation between changes in blood pressure and behavioral or neural effects (left column of Figure S1E ). However, given the known relationship between NE signaling and hemodynamics, it is important to rule out the possibility that changes in neurovascular coupling have led to the changes we observed in BOLD activity ( Figure 5 ). Indeed, several considerations suggest that this alone cannot explain the observed fMRI effects. First and most importantly, the electrophysiological (EEG) results support an underlying neural source for the effects. Second, hemodynamic effects are more likely to manifest as a global reduction of the BOLD signal across the wide cortical territories and across all levels of image contrast. However, the observed effects are highly localized to high-level visual areas around LO and evident only for low-contrast stimuli. Third, even higher dosages of clonidine and reboxetine that have been shown to induce local changes in blood flow have been reported not to affect blood flow in visual regions [66, 67] .
To what extent are sensory effects specific for noradrenaline? Several lines of converging evidence point to a key role for NE in facilitating sensory awareness and sensory-evoked activity, but given the redundancy in neuromodulatory activities, other systems likely exert overlapping effects. Our NE manipulation cannot rule out the contribution of other neuromodulatory activities, all the more so with a systemic manipulation that may lead to global neuromodulatory changes over long timescales. In addition, the drugs used here (e.g., reboxetine), although considered NE specific, do not exclusively influence the norepinephrine transporter (NET) and may also affect other modulatory transporters (e.g., serotonin). Notwithstanding these challenges, the present results establish that it is sufficient to systemically interfere with NE signaling to modulate perception and sensory-evoked activity. Future studies that will manipulate NE and compare its effects with those of other neuromodulators using identical experimental paradigms can shed additional light on the specificity of NE signaling in sensory awareness.
Conclusions NE signaling has been implicated in arousal, attention, emotion, decision making, and metacognitive function. Here, we provide evidence for a causal role of noradrenergic tone in basic sensory perception by modulating noradrenaline levels in healthy participants and examining the effects on visual perception and visually evoked activities. We find that although early stages of sensory processing remain largely intact with lower NE signaling-as is the case during sleep-NE presence is an essential causal factor that enables full-fledged processing at later stages associated with the emergence of conscious perception. Viewing perception as cortical ''ignition'' [68, 69] , NE might serve as ''fuel'' that facilitates the reverberatory ''fire'' of sensory activity. These results highlight the possibility that identical mechanisms (such as noradrenergic signaling) may affect sensory processing across sleep and wake states as well as during dynamic cognitive states-two fields of research that might be intimately linked yet are typically studied separately.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS Participants
All participants (n = 30) provided written informed consent and were paid for their participation. The study was approved by the Medical Institutional Review Board at the Tel-Aviv Sourasky Medical Center. Twenty four healthy male volunteers (mean age 24.5 years, range 21-31 years; 21 right-handed) took part in Experiment 1 (behavioral and EEG), 19 of which completed all three sessions and whose data entered subsequent analyses. Six healthy volunteers (2 women; mean age 27.16, range 25-32, all right handed) participated in Experiment 2 (fMRI), all of which completed all three sessions. Male participants were preferred due to the pregnancy and pharmacology inherent concern in female participants. All participants had normal or corrected to normal vision, and underwent medical screening by a physician (H.S.) that included a medical history questionnaire and interview, blood pressure measurements, and an electrocardiogram. Exclusion criteria included abnormal resting heart rate, non-sinus cardiac rhythm or abnormal blood pressure (systolic pressure < 100 mm Hg), history of psychiatric admissions and/or neuropsychiatric medications, alcohol or other illegal substance abuse, history of vertigo, migraines or syncope/loss of consciousness in the past five years, and eligibility for MRI based on MRI-safety guidelines (for Experiment 2). All participants reported compliance with the instructions to abstain from caffeine 24h before the experiment, ensure full-night sleep before experiments, and eat a low-protein breakfast on the day of the experiment.
METHOD DETAILS Drugs
In order to reduce noradrenergic signaling we used Clonidine (Normopressan, Rafa Laboratories; 0.15mg), an a2-adrenergic agonist which inhibits NE release primarily by acting as presynaptic a2-adrenergic agonist [35] . Clonidine is clinically used as a antihypertensive drug, and its effects on blood pressure are mostly centrally mediated [73] . Clonidine has a half-life of $7.5h, and peak plasma levels occur $2hr post-ingestion [36] . In order to boost noradrenergic signaling we employed Reboxetine (Edronax, Pfizer; 4 mg), a selective NE reuptake inhibitor (SNRI [37] ). Reboxetine has a half-life of 13h and peak plasma levels occur $2hr post ingestion [38] . Drugs were administered orally at fixed doses (0.15mg Clonidine and 4mg Reboxetine) based on the literature [74, 75] and patients' safety. Clonidine, Reboxetine and Placebo (sucrose) were administered orally in identical capsules while participants kept their eyes shut. Capsules were prepared in identical tubes with the number of session denoted on them so that the experimenter was also blind to the drug used. Order of drugs was pseudorandomly chosen to ensure that all six possible orders get an equal representation. Of note, as a specific NE-reuptake-inhibitor (SNRI), the effects of Reboxetine are not equivalent to the ''opposite'' of an a2 agonist which primarily reduce NE release via auto-receptors. Although a symmetric pharmacological manipulation could have been informative, a2 antagonists (such as Yohimbine) are associated with a serious side-effect profile [76, 77] and are best avoided in healthy volunteers.
Peripheral and subjective measures of arousal All measures of peripheral and subjective arousal ( Figure 1 ) were computed as percent change from the baseline values measured at drug administration (time zero), to go beyond variability unrelated to the pharmacological manipulation. Blood pressure Systolic (SP) and Diastolic (DP) blood pressure were measured at [-1, 0, 0.5, 1, 1.5, 2, 3hr] relative to drug administration. Mean Arterial Pressure (MAP, Figure 1B ) was calculated as 2=3DP + 1=3SP.
Subjective vigilance
Subjective sleepiness reports were collected at [-1, 0, 0.5, 1, 1.5, 2, 3hr] relative to drug administration, and at the end of each experiment, using the Stanford Sleepiness Scale (SSS) [78] ranging from 1 to 7: 1 -Feeling active, vital, alert, or wide awake; 2 -Functioning at high levels, but not at peak, able to concentrate; 3 -Awake, but relaxed, responsive but not fully alert; 4 -Somewhat foggy, let down; 5 -Foggy, losing interest in remaining awake, slowed down; 6 -Sleepy, woozy, fighting sleep, prefer to lie down; 7 -No longer fighting sleep, sleep onset soon, having dream-like thoughts. Vigilance index ( Figure 1C ) was calculated as [7 -(sleepiness score)] so that lower scores reflect lower levels of subjective arousal. Baseline pupil diameter At the beginning of each behavioral and EEG experiment, subjects were instructed to fixate on a central fixation point for 5 s. Pupil diameter during the last 3 s of these periods was averaged per subject, separately for the before-and after-sessions, for each drug condition ( Figure 1D ).
Behavior and EEG experiment design and setup

Study design
We employed a placebo-controlled, double blind, within-subject crossover study design. Each participant took part in three 4hr experimental sessions conducted a week apart at the same time of day (starting time, always between 7:30-10am, was identical across all three sessions in each participant). The order of drug administration (Placebo, Clonidine or Reboxetine) was balanced across participants. Each experimental session included a ''before-drug'' behavioral session conducted 1hr prior to drug administration, a 2hr wait period, and a 1hr ''after-drug'' behavioral and EEG session ( Figure 1A ). The ''before-drug'' behavioral session was used to set visual detection and discrimination thresholds for each participant and testing day separately, and before-drug performance was used as a reference to evaluate potential drug-induced changes later on, thereby implementing a ''within-session'' approach. ''Before-drug'' sessions included a subjective staircase paradigm, as well as liminal visual detection and discrimination paradigms (see below). The ''after-drug'' behavioral session (2h later) included concomitant EEG recording, identical liminal visual detection and discrimination paradigms, as well as an additional supraliminal visual discrimination paradigm. For one participant, thresholds were erroneously set to different values in the before and after sessions and these data were therefore excluded from analysis of behavioral data. Setup Experiments were conducted in an acoustically attenuated and electrically shielded room with a steady dim light. Gabor stimuli (4 of visual angle, 2 cycles per visual degree) were created and presented using the Psychtoolbox3 package for MATLAB [70] . Images were displayed on a 23'' LED monitor (HP 2311x) with a spatial resolution of 1920X1080 pixels and a vertical refresh rate of 60Hz, placed 90cm in front of the participant. A chin rest was used to maintain a constant viewing distance and head position. Behavioral responses were collected with a millisecond-accurate keyboard (DirectIN Keyboard v2014, Empirisoft). Pupil diameter was measured with a non-invasive monocular infrared eye tracking system at 1,000Hz ('Eyelink-1000', SR Research).
EEG recordings and preprocessing EEG recordings
High-density EEG was recorded continuously using a 256-channel hydrocel geodesic sensor net (Electrical Geodesics, Inc. system [EGI]). Each carbon-fiber electrode consists of a silver-chloride carbon fiber pellet, a lead wire, a gold-plated pin, and was injected with conductive gel (Electro-Cap International [ECI]). Signals were referenced to Cz, amplified via an AC-coupled high-input impedance amplifier (NetAmps 300, EGI), and digitized at 1000Hz. Electrode impedance in all sensors was lower than 50 kU at recording onset. EEG preprocessing EEG processing was performed in MATLAB (The MathWorks) using the FieldTrip [79] and EEGLAB [71] toolboxes and custom-written scripts. Peripheral electrodes (placed on neck and cheeks) were excluded from the analysis, leaving 192 electrodes for subsequent analysis. Data were down-sampled to 250Hz and filtered digitally between 0.3Hz and 45Hz. An additional 50Hz notch-filter and linear de-trending were applied to remove residual line noise and ultra-slow dynamics, respectively. Continuous data were segmented into trials/epochs of [-1500, 2100ms] around stimulus onset. Bad channels (< 20% in all participants) were identified as those electrodes whose variance and maximal absolute value constituted outliers relative to adjacent electrodes upon visual inspection per participant, and were interpolated using a linear, distance weighted interpolation. Artifact trials (< 20% in all participants) were identified as those epochs whose variance and maximal absolute value constituted outliers relative to all trials, and were discarded from subsequent analysis. Two subjects were discarded from EEG analysis of the supraliminal visual discrimination paradigm due to noisy data. Independent component analysis (ICA) was performed on the remaining electrodes to remove residual eye movement/heartbeat components. The number of trials was equated for each subject across the different experimental sessions (Clonidine, Reboxetine and placebo) by randomly discarding excessive trials. Trials were averaged per drug per subject and the resulting event-related potentials (ERPs, Figures 4B, S3B, S3D , S3E, and S4A) were baseline-corrected to the average voltage in the interval [-500, 0ms] before stimulus onset.
Behavioral and EEG experiment behavioral paradigms
In all behavioral paradigms the color of a central fixation point (0.2 visual angle) signaled the different stages of the trial: red for stimulus presentation, green for report, and black during inter-trial intervals; Trials were self-paced and initiated by a button press. Participants were required to fixate during the entire paradigm, except from planned breaks that occurred every 2-3min and in which an ''encouraging'' message was displayed on screen. In addition to the main task in each paradigm, participants (excluding 6 first participants) also reported rare occurrences (5%-8% of trials) of short empty black fixation circles (150ms duration) by a button press, and accuracy on this task was used as a measure of sustained attention levels. Participants received an immediate feedback for each attention-task trial. This parallel sustained-attention task was introduced after the first six participants to assist in separating potential sedative effects from perceptual effects, without introducing further changes to any other aspect of the paradigm. Subjective staircase paradigm Luminance contrast associated with threshold detection was evaluated in each testing day separately using a subjective staircase paradigm. A trial started with a 300-700ms of pre-stimulus red-fixation, followed by 100ms central presentation of a left-or right-tilted threshold contrast Gabor patch (4 of visual angel; 2 cycles per visual degree), and 800ms post-stimulation red fixation. Next, a green fixation appeared prompting participants to report presence/absence of stimulus by pressing the up/down arrows, respectively (Figure 2A) . Initial contrast was set to a medium level, easily noticeable by all participants, and the contrast in the next trial was adjusted by 1dB based on the response in the previous trial: C t+1 = C t x10 0.1 (when the last trial was seen) or C t+1 = C t /10 0.1 (when the last trial was unseen). After ten reversals the multiplication factor was lowered to 1.05 (instead of 10 0.1 = 1.26). The staircase procedure ended after fifteen reversals of the direction of contrast change, or after a maximum of ten minutes. Subjective contrast threshold (SCT) was set to the mean contrast value in the last six reversals. Liminal visual detection paradigm 50 zero-contrast trials, 45 SCT trials and five above threshold trials in which the contrast was 10%-50% above SCT were presented in a pseudo-random order. Trials were identical to the subjective staircase paradigm except a fixation interval with variable duration (700-1000ms) post-stimulation (Figure 2A ). In the before-drug session, SCT was manually adjusted after a few trials if performance was not satisfactory ($50% hits and $0% false alarms; SCT detection ). An identical SCT detection was used in the after-drug session. Liminal visual discrimination paradigm 76 SCT trials and eight trials with contrast 10%-50% above SCT were presented in a pseudo-random order. In the before-drug session, SCT was manually adjusted after a few trials if performance was not satisfactory ($75% correct; SCT discrimination ). An identical SCT discrimination was used in the after-drug session. Trials were identical to the subjective staircase paradigm except for a pre-stimulation fixation interval with variable duration (800-1200ms) and a 1500ms post-stimulation fixation interval. Here subjects indicated Gabor orientation by pressing the left or right-arrow buttons and then rated their subjective visibility on a 0-3 perceptual awareness scale (PAS; 0 = no experience, 1 = vague experience, 2 = almost clear experience and 3 = clear experience; Figure 2B ). Supraliminal visual discrimination paradigm This paradigm was identical to the liminal discrimination paradigm ( Figure 2B ), but with 76 supraliminal (10% contrast) Gabor patches, and without the PAS rating after each trial.
fMRI experiment design A placebo-controlled, double blind, within-subject crossover study was performed with the order of drugs (Placebo, Clonidine or Reboxetine) balanced across participants. Each participant took part in three 3hr experimental sessions conducted a week apart at the same time of day. Participants were blindly administered the drug upon arrival and were scanned 2hr later. Each scanning session included 2 repetitions of an event-related discrimination paradigm and anatomical scans. One of the experimental sessions also contained a visual localizer to delineate the borders of object-selective areas.
fMRI recordings and preprocessing
Functional imaging
Imaging was performed on a 3T Signa EXCITE MRI scanner (GE) with a resonant gradient echo planar imaging system. All images were acquired using a transmit-receive quadrature head coil. The scanning session included functional T2*-weighted images (discrimination paradigms: FOV = 220 mm, matrix size = 96 3 96, voxel size: 3 3 3 3 4mm, TR/TE = 2000/30, slice thickness = 4 mm, 26 nearly axial slices without gap covering the entire brain, interleaved slice order, flip angle 80
; visual localizer paradigm: same parameters except voxel size: 3 3 3 3 3mm, TR/TE = 3000/35, slice thickness = 3 mm, 39 slices, flip angle = 90
) and a three-dimensional (3D) anatomical scan using T1 SPGR sequence (1 3 1 3 1 mm) . Stimuli were generated on a PC, projected via an LCD projector (Epson MP 7200) onto a screen positioned at the back end of the MRI tunnel, and viewed through a tilted mirror, positioned over the subject's forehead. Stimulus presentation was controlled using Psychtoolbox 3 package for MATLAB. A fiberoptic MR-compatible response box (Current Designs, HHSC-1X4-L) was used to collect the responses. fMRI preprocessing Data were analyzed using BrainVoyager QX (Brain Innovation) and in-house MATLAB scripts. The first three images of each functional scan were discarded to avoid T1 saturation effects. Scans showing sharp head movements (> 1mm) were excluded from analysis (2 out of 18 scans). Preprocessing of functional scans included cubic spline slice-time correction, trilinear 3D motion correction, linear trend removal, filtering out low-frequency activities below 0.005Hz., coregistration with anatomical data, normalization to Talairach space [72] , and spatial smoothing using a Gaussian filter of FWHM = 6mm. Flattened cortical maps For display purposes only, contrast maps between drugs are presented on a flattened map ( Figure 5A ) generated as follows. The cortical surface of a normalized Talairach brain was reconstructed from a 3D SPGR scan. The procedure included segmentation of the white matter using a grow-region function, the smooth covering of a sphere around the segmented region, and the expansion of the reconstructed white matter into the gray matter. The surface of each hemisphere was then unfolded, cut along the calcarine sulcus and additional predefined anatomical landmarks on the medial side, and flattened.
fMRI experiment behavioral paradigms Object discrimination paradigm Stimuli consisted of 90 line-drawings of different tools and 18 different geometrical patterns presented on a gray background (Figure 5B ; 4.1 3 4.1 ), with a superimposed central red fixation point (0.14 3 0.14 ) throughout. The experiment included 5 conditions: tools images at three contrast levels (100%, 10% and 4%; 30 repetitions each) and geometrical patterns at two contrast levels (100% and 10%; 18 repetitions each). Images were presented for 200ms with interleaving fixations of 2-12 s in a rapid event-related paradigm. The experiment began and ended with 12 s of fixation and lasted 500 s. Subjects' task was to report by a button press if the presented tool ''fits in a shoebox'' or not, or if the presented geometrical pattern contains squares or not. Presentation sequence (condition order and timings) was optimized by the opsteq software (http://surfer.nmr.mgh.harvard.edu/optseq), to allow deconvolution of the hemodynamic response despite the rapid presentation of stimuli [80] .
Visual localizer paradigm
This experiment lasted 450 s and consisted of 4 conditions: grayscale still photographs (4.1 3 4.1 ) of faces, tools, houses and geometrical patterns (56 images from each category). Each condition was repeated 7 times in a controlled and counterbalanced block-design paradigm. Each block lasted 9 s, with interleaving 6 s fixations between blocks. The first and last fixations lasted 18 s and 12 s, respectively. A block consisted of 9 different stimuli; each stimulus was presented for 800ms and was followed by a 200ms fixation screen. A central red fixation point (0.14 3 0.14 ) was present throughout the experiment. One or two repetitions of the same image occurred in each block. Subject's task was to report by a button press whether the presented stimulus was identical to the previous stimulus or not (''1-back''). The visual localizer experiment was used to define unbiased regions of interest (ROIs) for analysis of the discrimination experiment data.
QUANTIFICATION AND STATISTICAL ANALYSIS
Analysis of behavioral measures in detection paradigm Sensitivity index (d') and response-bias/criterion (c) were calculated from the detection/hit rate (HR) and false-alarm rate (FAR) as follows: d 0 = zðHRÞ À zðFARÞ and c = À 1=2ðzðHRÞ + zðFARÞÞ, where z is the inverse of the cumulative standard normal distribution function [81] .
Permutation-based statistical analysis of drug order effects A permutation-based drug-order analysis was conducted on different measures (behavioral, EEG, fMRI) to test our drug order hypothesis, i.e., normal (placebo) response is better than response under reduced NE signaling (Clonidine, NE-) but worse than response under enhanced NE signaling (Reboxetine, NE+): NE-< placebo < NE+. We counted the number of observations obtained in the hypothesized order (i.e., Clonidine observations that were lower than both placebo and Reboxetine, placebo observations that were in-between Clonidine and Reboxetine, and Reboxetine observations that were higher than both placebo and Clonidine). The distribution of number of hypothesized order observations obtained by chance was estimated by repeating the analysis 100,000 times with drug labels randomly shuffled within subject. The p value is the relative ranking of the actual number of hypothesized order observations in this distribution, e.g., if the actual number was higher than 95% of the permutated values, it was given a p value of 0.05. See Figures S2C-S2E for detailed examples of the analysis. This analysis is comparable to the calculation of the cumulative binomial probability with probability of success = 3/6 (6 possible permutations of drug-order, out of which 3 are compatible with our hypothesis: NE-< Placebo < NE+, NE-< NE+ < Placebo and Placebo < NE-< NE+). However as opposed to the cumulative binomial probability where all options are given an equal weight, here the complete order (NE-< Placebo < NE+) is given a weight that is 3 times bigger relative to the 2 other incomplete options. Importantly the cumulative binomial probability analysis with probability of success = 3/6 (as described above), or with probability of success = 1/6 (counting only NE-< Placebo < NE+) yielded the same pattern of results.
EEG time frequency analysis
Inter-Trial Phase Coherence (ITPC) measure in the occipital ROI (Oz and its eight closest-neighbors, inset in Figure 4B ) was computed separately for each subject and drug, using segmented [-1500, 2100ms] stimulus-locked data, and a zero-padded, hanning tapered Morlet wavelet decomposition as implemented in EEGLAB newtimef function. Wavelets were defined such that 2 cycles were used at the lowest frequency (2Hz), increasing linearly to 7 cycles at the highest frequency (50Hz), to account for the trade-off between frequency and temporal resolution. A time-frequency ''region of interest'' (tfROI, demonstrated by rectangle in Figure 4A ) was defined manually to capture the prominent spectro-temporal features of the group averaged EEG response. The mean ITPC for this tfROI was calculated separately for each subject and drug condition for subsequent comparisons between drug conditions (for a detailed description of the ITPC calculation method see [71] ).
Statistical analysis of supraliminal visual discrimination EEG results
Population-level ERPs (N = 17) were compared between each drug and placebo using the cluster-based permutation t test (bottom bar in Figure S4A [43]), which identifies temporal intervals showing significant differences between conditions while correcting for multiple comparisons. This procedure was applied on data from a pre-determined occipital ROI at the [-200 , 1000ms] time window. Individual samples with p values < 0.01 were clustered based on temporal adjacency. Each temporal cluster was assigned a clusterlevel statistic corresponding to the sum of the t-values of the samples belonging to that cluster. The distribution of maximal clusterlevel statistics obtained by chance was estimated by repeating the analysis 10,000 times with drug labels randomly shuffled within subject. The cluster-level p value is the relative ranking of the cluster-level statistic in this distribution.
fMRI contrast between drugs maps
Contrasts between data associated with the different drugs, acquired in different recording sessions, were calculated through the use of dummy-coded variables: design matrix of each drug contained predictors for all three drugs, but the predictors for the two other drugs were zero-weighted. Such parameterization is common in univariate mixed-model approaches for repeated-measures designs [82] .
fMRI deconvolution analysis Using a general linear model, the hemodynamic response function was estimated for each event type using deconvolution. The time of the onset of the target and the following 7 time points (0-14 s) was used to estimate scaled fit coefficients (beta weights) at each of the modeled time points for each event.
